Kamada Ltd
KMDAStock
$6.91−5.42%52W
Market Cap$399.53M
P/E19.78x
Div yield3.50%
Beta0.88
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-18.49%
Price vs S&P 500 (4W)-4.75%
VGM Score52.42
Market Capitalization$399.53M
P/E Ratio (Annual)19.78x
Indicated Dividend Yield (Annual)3.50%
Earnings Surprise History
Q1 260.07est. 0.12
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.22
4.22
4.22
4.22
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KMDAKamada Ltd | C | C | C | $6.91 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Kamada Ltd is a biopharmaceutical company that develops and markets plasma-derived protein therapeutics for specialty diseases across multiple therapeutic areas including hemophilia, lung disease, immunoglobulin deficiencies, vaccines, critical care, and diagnostics. The company's proprietary portfolio includes key products such as Glassia, Bramitob, Foster, and Ixiaro. Revenue is primarily generated from proprietary products, with a secondary distribution segment.